News
More good safety results as Prescient Therapeutics continues cancer treatment tests
Australian biotech company Prescient Therapeutics has successfully finished a round of safety testing on its PTX-100 drug in a basket trial of patients with solid…
News
Prescient Therapeutics (ASX:PTX) expands trial of PTX-100
Prescient Therapeutics (PTX) is progressing the trial of its cancer-blocking drug PTX100 following successful results from Phase 1b of the trial. The cancer treatment company…
News
US drug administration signals further support for CAR-T cancer treatments
The US Food and Drug Administration has assigned a fast track designation to a new CAR-T cancer treatment for multiple myeloma patients. The designation comes…
News
Prescient Therapeutics delivers positive immune response test results
Shares in biotech company, Prescient Therapeutics, have proved buoyant this week after initial immunogenicity testing demonstrated the company’s OmniCAR binding systems for next-generation CAR-T therapies…
News
Positive results from immunogenicity testing send Prescient’s shares higher
In an upbeat development, Prescient Therapeutics Limited (ASX:PTX) has announced outstanding findings from in silico immunogenicity testing of OmniCAR’s key binding components – SpyTag and…
News
The Prescient (ASX:PTX) share price rocketed 10% higher today. Here’s why
Shares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of news its cancer treatment drug, OmniCAR, has been…
News
Prescient Therapeutics (ASX:PTX) returns successful immunogenicity results
Prescient Therapeutics (PTX) says recent results from testing show its entire platform has been substantially de-risked. In silico immunogenicity testing of the company’s OmniCAR key…
News
Prescient shares rip higher as immunogenicity testing results for OmniCAR ‘could not have been better’
The results significantly de-risk the project as PTX continues development of its OmniCAR platform. As it builds out its OmniCAR cancer treatment platform, clinical stage…
News
Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a sobering reminder of the dangers involved in cell therapy. Image: Getty Safety in mind as Prescient Therapeutics develops next-generation CAR-T platform
Tragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy after the deaths of two patients, a…
News
Prescient Therapeutics reaches a major CAR-T manufacturing milestone
In a milestone development regarding its innovative CAR-T cancer therapy programs, Prescient Therapeutics Limited (ASX:PTX) has announced that it has successfully completed the manufacturing and…